Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage
Cardiovasc Diabetol. 2026 Jul 24;25(1):210. doi: 10.1186/s12933-026-03292-z.ABSTRACTBACKGROUND: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) provide cardiovascular and renal protection in both diabetic and non-diabetic patients at least in part independently of glycaemic control. Some un

